In particular, higher expression of PD-L1 on antigen-presenting cells as well as on cancer cells is known to engage with PD-1 on activated CD8+ T cells, thereby inhibiting their cancer response (Han et al., 2020). This evidence concerns the gene CD8A and cancer.